References
- Rossler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399–409.
- Miyamoto S, Wolfgang Fleischhacker W. The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry. 2017;4(2):117–126.
- McCreath J, Larson E, Bharatiya P, et al. Long-acting injectable antipsychotics for schizophrenia: sociodemographic characteristics and treatment adherence. Prim Care Companion CNS Disord. 2017;19(1). DOI:10.4088/PCC.16m02005
- Rubio JM, Taipale H, Correll CU, et al. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol Med. 2019;13:1–12.
- Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213.
- Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561.
- Morrato EH, Parks J, Campagna EJ, et al. Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence. J Comp Eff Res. 2015;4(2):89–99.
- Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127–134.
- Smeraldi E, Cavallaro R, Folnegovi-Malc V, et al. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Ther Adv Psychopharmacol. 2013;3(4):191–199.
- Lambert M, De Marinis T, Pfeil J, et al. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry. 2010;25(4):220–229.
- Macfadden W, DeSouza C, Crivera C, et al. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry. 2011;11(1):167.
- Sugawara N, Kudo S, Ishioka M, et al. Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan. Neuropsychiatr Dis Treat. 2019;15:205–211.
- Fujii Y. Jikousei Chuusha seizai no subete (all about long acting treatment). Japan: Seiwa Shoten; 2018.
- Central social insurance medical council. 434th Central Social Insurance Medical Council General Meeting (Chuikyo Soukai) Handout; 2019; [cited 2020 Feb]. Available from: https://www.mhlw.go.jp/content/12404000/000568660.pdf
- Heres S, Hamann J, Kissling W, et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006;67(12):1948–1953.
- Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C.
- Ministry of Health Labor and Welfare. Medical economic survey 2017; 2017; [cited 2020 Feb]. Available from: https://www.mhlw.go.jp/bunya/iryouhoken/database/zenpan/jittaityousa/dl/21_houkoku_iryoukikan.pdf
- Oshima I, Mino Y, Inomata Y. How many long-stay schizophrenia patients can be discharged in Japan? Psychiatry Clin Neurosci. 2007;61(1):71–77.
- Ministry of Health Labor and Welfare. 90th Sectional Meeting for the Disabilities in the Social Security Council; 2018; [cited 2020 Feb]. Available from: https://www.mhlw.go.jp/content/12201000/000307970.pdf
- OECD. Hospital beds (indicator); 2020; [cited 2020 Feb 5]. Available from: https://data.oecd.org/healtheqt/hospital-beds.htm
- Nakamura Y, Shibata I, Mahlich J. Modeling the choice between risperidone long-acting injectable and generic risperidone from the perspective of a Japanese hospital. Neurol Ther. 2019;8(2):433–447.
- Ministry of Health Labor and Welfare. An outline of the Japanese medical system; 2019; [cited 2020 Feb]. Available from: https://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01\_eng.pdf
- The Japanese Society of Neuropsychopharmacology. Medication guideline of schizophrenia; 2015; [cited 2020 Mar]. Available from: http://www.asas.or.jp/jsnp/img/csrinfo/togoshiccho_01.pdf
- Central Social Insurance Medical Council. 385th Central Social Insurance Medical Council General Meeting (Chuikyo Soukai) Handout 2018; 2018; [cited 2020 Mar]. Available from: https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000191569.pdf
- Ministry of Health Labor and Welfare. Hospital report 2018; 2018; [cited 2020 Feb]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/kanja/14/dl/03.pdf
- Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363–370.
- Dassa D, Boyer L, Benoit M, et al. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44(10):921–928.